Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc. is well-positioned for growth in the metabolic therapeutics sector, as evidenced by the substantial 587% increase in prescriptions for GLP-1 drugs from 2019 to 2024, highlighting a significant shift in treatment paradigms for obesity and type 2 diabetes. The company anticipates sufficient manufacturing capacity to support its upcoming first-in-human Phase 1 trial, suggesting a streamlined pathway to scalability as their technologies evolve. Furthermore, data from the REMAIN-1 trial indicates the potential for Revita to achieve a peak penetration of 2%, bolstered by favorable outcomes in blood glucose control and improvements in lipid profiles, which may enhance Fractyl Health’s competitive positioning in the market.

Bears say

Fractyl Health Inc faces significant challenges in its financial outlook primarily due to high cash burn rates that may escalate with the expansion of development and commercial programs, and uncertainty regarding securing sufficient capital for ongoing projects like the Revita and Rejuva platforms. Additionally, the gradual loss of β-cell function in patients with type 2 diabetes presents a persistent obstacle to achieving durable therapeutic outcomes, as it necessitates complex and effective interventions to enhance insulin levels. Research indicates potential limitations in the efficacy of their approaches compared to existing pharmacological treatments, which may impact the company’s competitive standing and further jeopardize its financial viability.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.